Bio-Rad Laboratories, Inc.

Valuation Analysis

About the Company

Bio-Rad Laboratories, Inc. en bref

Bio-Rad Laboratories, Inc. (BIO) is currently trading at 246,44 € with a market capitalization of 6,6 Md €. The trailing P/E ratio stands at 47.07x, with a forward P/E of 29.05x. The 52-week range spans from 199,32 € to 299,43 €; the current price is 17.7% below the yearly high. Year-over-year revenue growth stands at +1.1%. The net profit margin stands at 6.52%.

💰 Dividende

Bio-Rad Laboratories, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

5 analystes évaluent Bio-Rad Laboratories, Inc. (BIO) au consensus : None. L'objectif de cours moyen est de 259,18 €, soit un potentiel de +5.17% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 239,99 € à 279,26 €.

Bio-Rad Laboratories, Inc. : la thèse d'investissement en détail

Bio-Rad Laboratories, Inc. (BIO) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue growth has slowed to just 1.1%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

At a PEG of 4.01, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

À surveiller

• The forward P/E of 29.05x is meaningfully below the trailing 47.07x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to market-like volatility.

Trading Data

Related Stocks in the Same Sector

Where can I buy Bio-Rad Laboratories, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.